What's the most recent regulatory action in Hypoprothrombinemia secondary to cystic fibrosis of the pancreas?

Most recent: Vitamin K1 — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hypoprothrombinemia-secondary-to-cystic-fibrosis-of-the-pancreas.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hypoprothrombinemia secondary to cystic fibrosis of the pancreas — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hypoprothrombinemia secondary to cystic fibrosis of the pancreas (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hypoprothrombinemia secondary to cystic fibrosis of the pancreas, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Vitamin K1	Phytonadione	Pfizer Inc.	Vitamin K [EPC]	Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-13 — Vitamin K1 · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer Inc. · 1 drug in Hypoprothrombinemia secondary to cystic fibrosis of the pancreas

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hypoprothrombinemia secondary to cystic fibrosis of the pancreas:

Cite this brief

Drug Landscape (2026). Hypoprothrombinemia secondary to cystic fibrosis of the pancreas — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hypoprothrombinemia-secondary-to-cystic-fibrosis-of-the-pancreas. Accessed 2026-06-10.

Hypoprothrombinemia secondary to cystic fibrosis of the pancreas full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing